Summary
For Year 2026-27, Emcure Pharmaceuticals reports the following shareholding: Total Promoters at 77.87%, Mutual Fund at 4.83%, Insurance at 0.98%, Foreign Institutional Investors at 3.59%, Domestic Institutional Investors at 0.29%, and Retail at 12.44%. This breakdown provides a quick snapshot of ownership distribution for Emcure Pharmaceuticals in 2026-27.
Emcure Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Emcure Pharmaceuticals stands at 77.87% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Emcure Pharmaceuticals is 3.59% and 0.29% respectively.
The retail shareholding of the Emcure Pharmaceuticals is 12.44%.
Changes in shareholding patterns of Emcure Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Emcure Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Emcure Pharmaceuticals Associated Pages
- Emcure Pharmaceuticals Share Price
- Emcure Pharmaceuticals Share Price chart
- Emcure Pharmaceuticals Fundamental Analysis
- Emcure Pharmaceuticals Technical Analysis
- Emcure Pharmaceuticals Peer Comparison
- Emcure Pharmaceuticals Share Price History
- Emcure Pharmaceuticals Dividend
- Emcure Pharmaceuticals Board of Directors
